In Part I of this article series, the authors discussed the regression control chart method for identifying out-of-trend data in pharmaceutical stability studies. In Part II, the by-time-point method and the multivariate control chart method are investigated, and improved approaches are suggested. The method is illustrated using real data sets.
kentoh/shutterstock.com
This article is a continuation of Part I, in which the authors discussed the identification of out-of-trend (OOT) data in the stability studies of single batches using a regression control chart method (1).
If several batches are considered, there are two different time scales. The first one is the life within batches, which has been covered in Part I (1). The regression control chart uses this within-batch context. The second time scale is the order of batches. Two approaches are followed in this Part II article. The by-time-point method uses the between-batches context only, while the multivariate approach uses both between-batches and within-batches contexts.
Click here to view a PDF of this article.Peer-Review Article
Submitted: April 5, 2017
Accepted: June 27, 2017
Máté Mihalovits is a PhD student, mihalovits@mail.bme.hu; and Sándor Kemény* is an emeritus professor, Tel.: +36 309936307, kemeny@mail.bme.hu, both at Budapest University of Technology and Economics, Faculty of Chemical Technology and Biotechnology, Department of Chemical and Environmental Process Engineering Hungary, 1111. Budapest, Műegyetem rakpart 3.
* To whom all correspondence should be addressed.
Pharmaceutical Technology
Vol. 41, No. 12
December 2017
Pages: 38–43, 45
When referring to this article, please cite it as M. Mihalovits and S. Kemény, "Methods for Identifying Out-of-Trend Data in Analysis of Stability Measurements–Part II: By-Time-Point and Multivariate Control Chart," Pharmaceutical Technology 41 (12) 2017.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.